Concerns About Bone Loss: Other studies indicate that GLP-1 agonists may contribute to bone loss, particularly in individuals who experience rapid weight loss while using these drugs
A patient carrying a particular GLP1R variant might experience robust appetite suppression at microdose levels, while another individual with a different genetic profile may require standard dosing for the same effect
The liver critically controls postprandial carbohydrate levels by suppressing HGP and stimulating the deposition of glucose as glycogen and is the primary source of glucose production during fasting [35]
Endogenous ghrelin, primarily secreted by the stomach in response to fasting, exerts its growth hormone (GH)-stimulating effects by activating this same receptor located in the hypothalamus and pituitary gland
We currently have no large scale outcomes data on sublingual GLP-1s
(PubMed) Pozuelo-Moyano B, Benito-Leon J, Mitchell AJ, Hernandez-Gallego J